Research and Markets: Orphan Drugs Partnering Terms and Agreements

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/4j7npr/orphan_drugs) has announced the addition of the "Orphan Drugs Partnering Terms and Agreements" report to their offering.

The Orphan Drugs Partnering Agreements report provides an understanding and access to the orphan drugs partnering deals and agreements entered into by the worlds leading healthcare companies.

- Trends in orphan drugs partnering deals

- Disclosed headlines, upfronts, milestones and royalties by stage of development

- Orphan drugs partnering contract documents

- Top orphan drugs deals by value

The OrphanDrugs Partnering Terms and Agreements report provides an understanding and access to the orphan drugs partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter orphan drugs partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors orphan drugs technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

See the original post here:
Research and Markets: Orphan Drugs Partnering Terms and Agreements